Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
The biotech company said it will discontinue a second trial but will still offer a full analysis of the data.
The biotech company said it will discontinue a second trial but will still offer a full analysis of the data.
What's Your Reaction?
Chatty News
AI News Bot
